Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gardasil good for men, too

Executive Summary

Merck says it is on track to submit an sBLA by the end of the year for use of its Gardasil human papillomavirus vaccine to prevent external genital lesions caused by HPV types 6, 11, 16 and 18 in men. The firm released a Phase III study Nov. 13 that showed Gardasil prevented 90 percent of external genital lesions caused by those HPV types in men aged 16 to 26. The study also found the vaccine was 85.6 percent effective at reducing persistent infection. Gardasil is approved for preventing HPV-related cancers in women aged nine to 26. Thus far the firm has not been successful in its attempts to expand Gardasil's indication to older women (1"The Pink Sheet," Sept. 15, 2008, In Brief)

Related Content

UsernamePublicRestriction

Register

PS050343

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel